Protara Therapeutics Inc [TARA] stock prices are down -6.95% to $5.22 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TARA shares have gain 5.24% over the last week, with a monthly amount glided 63.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protara Therapeutics Inc [NASDAQ: TARA] stock has seen the most recent analyst activity on April 16, 2025, when Scotiabank initiated its Sector Outperform rating and assigned the stock a price target of $12. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $40 on June 04, 2021. Oppenheimer initiated its recommendation with a Outperform and recommended $43 as its price target on February 17, 2021. Cowen started tracking with a Outperform rating for this stock on October 19, 2020, and assigned it a price target of $50. In a note dated July 29, 2020, Guggenheim initiated a Buy rating and provided a target price of $50 on this stock.
The stock price of Protara Therapeutics Inc [TARA] has been fluctuating between $1.60 and $10.48 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Protara Therapeutics Inc [NASDAQ: TARA] shares were valued at $5.22 at the most recent close of the market. An investor can expect a potential return of 129.89% based on the average TARA price forecast.
Analyzing the TARA fundamentals
Gross Profit Margin for this corporation currently stands at -0.3% with Operating Profit Margin at -172.75%, Pretax Profit Margin comes in at -153.2%, and Net Profit Margin reading is -153.2%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.37 and Total Capital is -0.39. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Protara Therapeutics Inc [NASDAQ:TARA]’s Current Ratio is 12.82. In addition, the Quick Ratio stands at 12.82 and the Cash Ratio stands at 3.23.
Transactions by insiders
Recent insider trading involved Levy Richard S, Director, that happened on May 14 ’25 when 20000.0 shares were purchased. Chf Scientific Operations Off, Zummo Jacqueline completed a deal on Mar 26 ’25 to sell 21224.0 shares. Meanwhile, Officer Zummo Jacqueline bought 21224.0 shares on Mar 26 ’25.
